TrialCancer2025

Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).

Alexander M Menzies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.